fgf 2

Sucralfate (Sucrose octasulfate–aluminum complex) 是一种口服活性胃保护剂。它抑制消化性活性，并与黏膜损伤时暴露的带负电荷的上皮下蛋白结合，形成一层粘性层，保护血管床和增殖区。它可用于预防和治疗胃肠道疾病。

Surfen dihydrochloride (Aminoquinuride dihydrochloride) 是一种有效的硫酸肝素小分子拮抗剂，具有抗菌和抗病毒活性，抑制炭疽致死因子、凝血因子 X 和致死因子。Surfen dihydrochloride 可抑制普通肝素和低分子量肝素的抗凝活性，抑制肝素的硫酸化和肝素裂解酶的降解。Surfen dihydrochloridn 抑制阻断硫酸乙酰肝素介导的 FGF2 结合和信号转导。Surfen 抑制 SEVI 和精液介导的 HIV 1 型感染增强。

FGF22-IN-1 是一种潜在的 CD4 N-末端免疫球蛋白可变区样结构域（CD4 D1）抑制剂。FGF22-IN-1 可抑制CD4 与主要组织相容性复合体 （MHC） II 类蛋白之间的相互作用，抑制免疫应答。

XRP44X (XRP 44X) 是Ras 诱导的转录激活的抑制剂，IC50为 10 nM，通过 FGF-2 抑制 Ras-Erk-1 2 通路激活。它抑制Elk3。它还对微管有影响。

CP-547632是一种可口服且具有有效性、ATP 竞争性的 血管内皮生长因子受体2（VEGFR-2 ）和 碱性成纤维细胞生长因子（FGF）激酶F 双重抑制剂，IC50 分别为 11 nM 和 9 nM。CP-547632具有选择性，对 VEGFR2 和 bFGF 的选择性高于 EGFR，PDGFRβ 和相关的酪氨酸激酶 (TKs) 。 CP-547632具有抗肿瘤活性。

CP-547632 hydrochloride is a well-tolerated and orally-bioavailable inhibitor of the VEGFR-2 and basic FGF kinases (IC50s: 11 nM and 9 nM) with antitumor efficacy.

UM4118 (N-quinolin-8-ylpyridine-2-carboxamide) 是一种铜离子载体，能引发一种基于线粒体的非典型形式的细胞死亡（cuproptosis）。UM4118 可用于研究急性髓系白血病。UM4118 对VEGF和b-FGF刺激的HMVEC增殖的LC值分别为0.013和0.018μM。

PKCε (85-92)（ψεRACK）是一种多肽和选择性PKCε激活剂，不影响其他PKC同工酶的活性。PKCε (85-92)可诱导内皮细胞的促血管生成反应，促进FGF-2胞吐，调节VEGF活性。

BMS-645737 is an inhibitor of vascular endothelial growth factor (VEGF) receptor-2 and fibroblast growth factor (FGF) receptor-1. BMS-646737 has anti-angiogenic activity and was evaluated in nonclinical studies as a treatment for cancer.

Sucrose octasulfate (SOS), a component of the gastrointestinal protectant sucralfate, is an alkaline aluminum-sucrose complex that inhibits peptic hydrolysis and raises gastric pH, protecting esophageal epithelium against acid injury. It can bind to exosite II of thrombin (KD = ~1.4 μM) and inhibit its catalytic activity (IC50 = 4.5 μM) and, as such, has been used as a surrogate for heparin. Furthermore, SOS has been shown to inhibit tumor growth in mouse melanoma and lung carcinoma models by preventing fibroblast growth factor 2 (FGF-2) binding to endothelial cells and also by removing any pre-bound FGF-2 from these cells (IC50 = ~2 μg/ml).

3-Methylthienyl-carbonyl-JNJ-7706621 is a highly potent and selective inhibitor of cyclin-dependent kinase (CDK). It exhibits impressive IC50 values of 6.4 nM and 2 nM for CDK1 cyclin B and CDK2 cyclin A, respectively. Additionally, 3-Methylthienyl-carbonyl-JNJ-7706621 demonstrates potent inhibition against GSK-3 (IC50 = 0.041 μM) and moderate potency towards CDK4, VEGF-R2, and FGF-R2 (IC50 = 0.11 μM, 0.13 μM, and 0.22 μM, respectively). Its applications in cancer research are noteworthy.

CP-547632 TFA是一款口服效果显著的ATP競爭性抑制劑，针对VEGFR-2和FGF激酶具有高度选择性，IC50值分别为11 nM和9 nM。该化合物相较于EGFR和PDGFRβ，对VEGFR2和bFGF展现出更高的选择性，优于相关的酪氨酸激酶（TKs）。CP-547632 TFA还显示了显著的抗肿瘤活性。

D-Glucosamine-6-sulfate is a naturally occurring glycosaminoglycan. It activates the glmS ribozyme from B. subtilis, a Gram-positive bacterium, when used at a concentration of 200 μM. It has been used to form polyvalent dendrimer conjugates that inhibit angiogenesis and endothelial cell proliferation induced by FGF-2 in vitro and prevent scar tissue formation in a rabbit model of glaucoma surgery.

AF3485作为一种人类mPGES-1抑制剂,不仅在体外展现了抗肿瘤活性,也在体内证实了其效能.该化合物通过降低PGE2的产生、抑制EGFR信号传导,并减少VEGF与FGF-2的表达,有效阻断了肿瘤相关的血管生成.在携带人类A431异种移植瘤的小鼠模型中,AF3485经亚慢性给药显著地抑制了肿瘤生长.

FGF PDGF VEGF RTK Inhibitor is a potent, reversible, atp-competitive inhibitor against pdgfrβ, fgfr-1, and vegfr-2 (ic50 = 20, 90, and 240 nm, respectively) and effectively suppresses vegf-stimulated proliferation of hmvecs (ec50 = 420 nm).

Synstatin (92-119)为一种抗肿瘤化合物，它能够抑制血管生成与癌细胞侵袭，通过下调整合素αvβ3，降低VEGF与FGF-2的活化。